Navigation Links
Branded Prescription Pharmaceutical Sales Outlook to 2016
Date:3/19/2012

NEW YORK, March 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Branded Prescription Pharmaceutical Sales Outlook to 2016

http://www.reportlinker.com/p0799256/Branded-Prescription-Pharmaceutical-Sales-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

In 2011, the Branded PharmaVitae Universe achieved sales of $558bn having experienced a compound annual growth rate (CAGR) of 9.3% between 2003 and 2010, and a net sales growth of $253bn. However, during 2011–16 sales are forecast to grow by a CAGR of only 1.0%, with no growth forecast in 2012, and branded prescription sales rising by just $29bn by 2016.Analyzes the forecast sales of the Branded PharmaVitae Universe according to molecule typeAnalyzes the forecast sales of the Branded PharmaVitae Universe according to therapy areaAnalyzes the forecast sales of the Branded PharmaVitae Universe according to geographical marketAnalyzes the forecast sales of the Branded PharmaVitae Universe according to formulation type

By 2016 the small molecule market will contract by $5bn compared to 2011 sales as a direct consequence of the patent cliff and resultant generic erosion of branded sales. In preparation for this, the pharmaceutical industry has for some years been shifting its strategy to focus increasingly on high-growth markets such as biologics.

With US sales forecast to contract, pharmaceutical companies have turned to cost cutting and restructuring their US operations, while expanding in the high growth emerging markets. In fact, branded sales in the rest of world markets are forecast to represent 30.0% of sales in the Branded PharmaVitae Universe in 2016.

The pharmaceutical industry is shifting its R&D focus toward developing novel, high value, and often biologic therapies for the treatment of more niche indications. Reflecting this, infectious diseases and oncology are forecast to experience strong growth with additional sales of $10bn and $26bn by 2016, respectively.

Evaluate the evolving prescription pharmaceutical landscape and how this is set to impact Pharma out to 2016Quantify the size and growth of the pharmaceutical marketAssess drivers and resistors of the prescription pharmaceutical market

EXECUTIVE SUMMARYStrategic scoping and focusKey findingsRelated reportsFORECAST PRESCRIPTION PHARMACEUTICAL SALES ANALYSISThe Branded PharmaVitae Universe will experience sales growth of only 1.0% per year out to 2016Newly launched and core drugs will collectively offset the sales loss from expiry productsThe pharmaceutical industry continues to expand in the biologic sector Injectable drugs are set to drive market growth The industry will derive the majority of its sales from externally sourced products by 2016The rest of world markets alone will offset the sales decline in the USSecondary care therapy areas are becoming a priority for pharmaSales of blockbuster drugs are expected to contract during 2011–16BIBLIOGRAPHYPublications and online articles Datamonitor reports and productsAPPENDIXThe Branded PharmaVitae Universe

TABLES

Table: Forecast prescription pharma sales ($bn) and year-on-year growth rate (%) for the Branded PharmaVitae Universe, 2011–16

Table: Combined global sales for the Branded PharmaVitae Universe for launch, core, expiring, and generic prescription products ($bn), 2011–16

Table: Combined global prescription sales for the Branded PharmaVitae Universe, by molecule type ($bn), 2011–16

Table: Combined global prescription sales for the Branded PharmaVitae Universe, by product delivery mechanism ($bn), 2011–16

Table: Combined global prescription sales for the Branded PharmaVitae Universe, by product source ($bn), 2011–16

Table: Combined prescription sales for the Branded PharmaVitae Universe, by geography ($bn), 2011–16

Table: Combined global prescription sales for the Branded PharmaVitae Universe, by therapy area ($bn), 2011–16

Table: Global prescription sales for the Branded PharmaVitae Universe, by product value ($bn), 2011–16

Table: Forecast sales for the Branded PharmaVitae Universe ($m), 2011–16

FIGURES

Figure: Drivers and resistors for global sales growth of prescription products from the Branded PharmaVitae Universe, 2011–16Figure: Global prescription pharma sales ($bn) and year-on-year growth rate (%), 2003–16Figure: Combined global sales for the Branded PharmaVitae Universe for launch, core, expiring, and generic prescription products ($bn), 2003–16Figure: Difference in global combined sales for the Branded PharmaVitae Universe for launch, core, expiring, and generic prescription products ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by launch/core/expiry/generic portfolio, 2011–16Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by molecule type ($bn), 2003–16Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by molecule type ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by molecule type, 2011–16Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by product delivery mechanism ($bn), 2003–16Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by product delivery mechanism ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by delivery mechanism, 2011–16Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by product source ($bn), 2003–16Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by product source ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by product source, 2011–16Figure: Combined prescription sales for the Branded PharmaVitae Universe, by geography ($bn), 2003–16Figure: Difference in combined prescription sales for the Branded PharmaVitae Universe, by geography ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by geography, 2011–16Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by therapy area ($bn), 2003–16Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by therapy area ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by therapy area, 2011–16Figure: Global prescription sales for the Branded PharmaVitae Universe, by product value ($bn), 2003–16Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by product value ($bn), 2011 and 2016Figure: Sales growth for the Branded PharmaVitae Universe, by product value, 2011–16

Companies mentioned

GlaxoSmithKline Plc, Hutchison 3G UK Limited, Johnson & Johnson, Merck KGaA, Schindler Holding Ltd., Telstra Corporation Limited

To order this report:Pharmaceutical Industry: Branded Prescription Pharmaceutical Sales Outlook to 2016

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
2. Lupin Expands Branded Play
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013
5. International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line
6. Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
7. Reportlinker Adds Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies
8. GNC Teams With Sakar International for Branded Health and Wellness Product Line
9. Branded Pharmaceutical Websites Continue to Be Most Impactful in Driving Conversions Among Prospects and Patients
10. Par Pharmaceutical Companies Announces a Restructuring of Its Branded Division, Strativa Pharmaceuticals, to Maximize Profitability
11. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) ... of ,world firsts,: , TwinLink™ - the ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
(Date:6/23/2016)... -- The National Pharmaceutical Council (NPC) today announced that ... organization as its newest member.  ... and chief scientific officer, Mallinckrodt Pharmaceuticals, will serve ... of Directors. ... in support of our efforts to conduct research ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
Breaking Medicine News(10 mins):